|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 04:21
|
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 (Business Wire)
|
|
|
Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum: $33.7 million of total revenue and other income, up from $26.4 million in Q2 2025.
Product Revenue: Up 434% in Q3 2025 versus Q3 2024, with year-to-date sales of $74.7 million.
ANKTIVA® Unit Growth: 467% unit sales volume growth in year-to-date 2025 compared to fiscal year 2024.
Cash Position: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025.
Glioblastoma: Early results from the first five recurrent glioblastoma patients treated with ANKTIVA plus the Optune Gio® device in combination with PD-L1 CAR-NK showed 100% disease control, including three responses (two near complete) and two cases of stable disease. Lymphocyte counts increased in all five patients. Based on these findings, ImmunityBio is initiating a randomized registration trial for second line GBM patients.
Non-Small Cell Lung Cancer (NSCLC): ImmunityBio has initiated enrollment i...
|
|
|
07.10.25 - 14:45
|
ImmunityBio: Zwischen Hype und Hoffnung (Sharedeals)
|
|
|
Die Aktie von ImmunityBio hat in den vergangenen eineinhalb Jahren deutlich an Wert verloren, nachdem Finanzierungsbedarf zu einer erheblichen Verwässerung führte. Dennoch rückt das Unternehmen dank seines Schlüsselprodukts Anktiva, vielversprechender Pipeline-Projekte und zunehmender Unterstützung durch Analysten wieder stärker in den Fokus. ImmunityBio ist ein biopharmazeutisches Unternehmen mit Sitz in San Diego, das auf Immuntherapien und […]
The post ImmunityBio: Zwischen Hype und Hoffnung first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 13:06
|
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code (Business Wire)
|
|
|
Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of approximately $43 million.
ANKTIVA® Unit Growth Since J-code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024.
Cash Position: $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025, with additional $80 million equity financing closed in July 2025, with warrants which could result in an additional gross proceeds of up to approximately $96.0 million.
Non-Small Cell Lung Cancer (NSCLC): ImmunityBio has launched ResQ201A, a randomized controlled trial (RCT), in the U.S., evaluating its IL-15 superagonist N-803 in combination with tislelizumab, a PD-1 CPI from BeOne Medicines in patients with second-line lung cancer who were progressing on checkpoint inhibitors (CPIs). The Company has also submitted clinical trial applications for ResQ201A in the EU and the UK, with Canada expected to be submitted in early Q3 2025, and with plans underway to s...
|
|
|
|
|
|
|
25.07.25 - 12:06
|
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors (Business Wire)
|
|
|
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million.
Piper Sandler & Co. is acting as the exclusive placement agent for the registered direct offering.
The securities to be sold by the Company are offered under its automatic shelf registration statement on F...
|
|
|
|
|
|
|
|
|
|
|
12.05.25 - 12:33
|
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code (Business Wire)
|
|
|
For the three months ended March 31, 2025—marking the first quarter with a permanent J-code that streamlined billing and reimbursement for prescribing providers—ImmunityBio achieved net product revenue of approximately $16.5 million, representing a 129% increase over $7.2 million in Q4 2024.
ANKTIVA® unit sales volume in Q1 2025 grew 150% over Q4 2024, with monthly volume in March up 69% over February.
Nearly 200 urology practices across the United States are in the process of registering for ImmunityBio's recombinant BCG (rBCG) Expanded Access Program (EAP), reflecting continued progress in ImmunityBio's efforts to address the Bacillus Calmette-Guérin (BCG) shortage and broaden the market for ANKTIVA.
At the recent American Urological Association Annual Meeting (AUA 2025), the company announced positive long-term results from the QUILT 3.032 study that showed the longest duration of complete response and highest rate of cystectomy avoidance within the non-muscle invasive bladder cancer (NMIBC) sp...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
